Despite these preliminary evidence, the exact relevance of CD73-adenosine signaling in both EGFR-mutated tumor cells and infiltrating immune cells to the efficacy of immune checkpoint inhibitors remains unclear. This evidence concerns the gene EGFR and neoplasm.